ML-60218 is an inhibitor of broad-spectrum RNA pol III with IC50s of 32 and 27 μM for Saccharomyces cerevisiae and human. ML-60218 disrupts already assembled viroplasms and hampers the formation of new viroplasms.

ML-60218 reverses SAHA-stimulated tRNA expression in PANC-1 and BxPC-3 cells. ML-60218 enhances the ability of HDAC inhibitors to induce apoptosis and cell cycle arrest. The combination of SAHA and ML-60218 produces enhanced suppression of proliferation in human pancreatic adenocarcinoma by impairing cell cycle progression and inducing apoptosis[1]. ML-60218 interferes with the formation of higher-order structures of VP6, the protein forming the DLP outer layer, without compromising its ability to trimerize. ML-60218-mediated (10 μM ) viroplasm disruption causes NSP5 dephosphorylation. Electron microscopy of ML-60218-treated DLPs shows dose-dependent structural damage[2].